 Max Wohlauer
Concepts (372)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Vascular Surgical Procedures | 16 | 2022 | 259 | 3.750 |
Why?
| | Endovascular Procedures | 8 | 2023 | 269 | 1.800 |
Why?
| | Peripheral Arterial Disease | 4 | 2022 | 380 | 1.270 |
Why?
| | Blood Coagulation Disorders | 10 | 2016 | 197 | 1.220 |
Why?
| | Blood Vessel Prosthesis Implantation | 6 | 2022 | 181 | 1.160 |
Why?
| | Surgeons | 6 | 2021 | 239 | 1.130 |
Why?
| | Thrombelastography | 13 | 2020 | 180 | 1.070 |
Why?
| | Vascular System Injuries | 3 | 2023 | 66 | 1.040 |
Why?
| | Acute Lung Injury | 8 | 2015 | 298 | 1.040 |
Why?
| | Aortic Aneurysm, Abdominal | 4 | 2022 | 113 | 0.980 |
Why?
| | Wounds and Injuries | 13 | 2016 | 745 | 0.910 |
Why?
| | Shock, Hemorrhagic | 9 | 2015 | 199 | 0.890 |
Why?
| | Burnout, Professional | 4 | 2021 | 322 | 0.880 |
Why?
| | Leg Injuries | 1 | 2023 | 20 | 0.850 |
Why?
| | Intermittent Claudication | 2 | 2022 | 108 | 0.840 |
Why?
| | Diabetic Foot | 1 | 2022 | 22 | 0.830 |
Why?
| | Elective Surgical Procedures | 2 | 2020 | 151 | 0.810 |
Why?
| | Mental Health | 3 | 2022 | 562 | 0.780 |
Why?
| | Blood Transfusion | 8 | 2016 | 293 | 0.760 |
Why?
| | Sexism | 1 | 2021 | 44 | 0.730 |
Why?
| | Cultural Diversity | 1 | 2021 | 54 | 0.730 |
Why?
| | Pneumonia, Viral | 3 | 2020 | 338 | 0.730 |
Why?
| | Coronavirus Infections | 3 | 2020 | 330 | 0.730 |
Why?
| | Internship and Residency | 4 | 2020 | 926 | 0.710 |
Why?
| | Ergonomics | 1 | 2020 | 23 | 0.710 |
Why?
| | Musculoskeletal Pain | 1 | 2020 | 23 | 0.710 |
Why?
| | Aortic Aneurysm, Thoracic | 3 | 2017 | 122 | 0.690 |
Why?
| | Pandemics | 8 | 2023 | 1317 | 0.670 |
Why?
| | Aggression | 1 | 2021 | 183 | 0.670 |
Why?
| | Muscle Fatigue | 1 | 2020 | 94 | 0.660 |
Why?
| | Racism | 1 | 2021 | 102 | 0.660 |
Why?
| | Multiple Organ Failure | 4 | 2013 | 146 | 0.660 |
Why?
| | Foot | 1 | 2020 | 103 | 0.660 |
Why?
| | Continuity of Patient Care | 2 | 2012 | 253 | 0.650 |
Why?
| | Occupational Diseases | 1 | 2020 | 128 | 0.640 |
Why?
| | Tendons | 1 | 2020 | 120 | 0.640 |
Why?
| | Betacoronavirus | 3 | 2020 | 250 | 0.630 |
Why?
| | Axillary Artery | 2 | 2015 | 12 | 0.620 |
Why?
| | Lymph | 3 | 2015 | 40 | 0.600 |
Why?
| | Running | 1 | 2020 | 207 | 0.590 |
Why?
| | Serum Albumin, Human | 1 | 2017 | 3 | 0.570 |
Why?
| | Vascular Diseases | 1 | 2020 | 230 | 0.570 |
Why?
| | Hypoalbuminemia | 1 | 2017 | 27 | 0.560 |
Why?
| | Attitude of Health Personnel | 2 | 2021 | 975 | 0.560 |
Why?
| | Curriculum | 3 | 2019 | 819 | 0.560 |
Why?
| | Research Design | 1 | 2022 | 928 | 0.550 |
Why?
| | Blood Platelet Disorders | 2 | 2013 | 10 | 0.510 |
Why?
| | Axilla | 1 | 2015 | 39 | 0.500 |
Why?
| | Aneurysm, False | 1 | 2015 | 45 | 0.490 |
Why?
| | Osteosarcoma | 1 | 2015 | 67 | 0.480 |
Why?
| | Diabetes Mellitus | 1 | 2022 | 900 | 0.480 |
Why?
| | Soft Tissue Neoplasms | 1 | 2015 | 90 | 0.470 |
Why?
| | Humans | 60 | 2023 | 114624 | 0.460 |
Why?
| | Bone Neoplasms | 1 | 2015 | 194 | 0.430 |
Why?
| | Physicians | 1 | 2021 | 772 | 0.430 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2021 | 1183 | 0.430 |
Why?
| | Neutrophils | 4 | 2015 | 1176 | 0.420 |
Why?
| | Matrix Metalloproteinase 13 | 1 | 2012 | 23 | 0.410 |
Why?
| | Patient Handoff | 1 | 2012 | 26 | 0.410 |
Why?
| | Duodenal Neoplasms | 1 | 2012 | 19 | 0.410 |
Why?
| | Carcinoma, Papillary | 1 | 2013 | 73 | 0.410 |
Why?
| | Common Bile Duct Neoplasms | 1 | 2012 | 24 | 0.410 |
Why?
| | Intestinal Volvulus | 1 | 2012 | 9 | 0.410 |
Why?
| | Ampulla of Vater | 1 | 2012 | 30 | 0.400 |
Why?
| | Saline Solution, Hypertonic | 1 | 2012 | 53 | 0.400 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2012 | 79 | 0.400 |
Why?
| | Colonic Diseases | 1 | 2012 | 25 | 0.400 |
Why?
| | Pancreatic Ducts | 1 | 2013 | 69 | 0.400 |
Why?
| | Blood Coagulation | 5 | 2021 | 218 | 0.400 |
Why?
| | Neoplasms, Multiple Primary | 1 | 2012 | 52 | 0.400 |
Why?
| | Multiple Trauma | 1 | 2012 | 96 | 0.380 |
Why?
| | Hemodilution | 1 | 2011 | 10 | 0.380 |
Why?
| | General Surgery | 1 | 2012 | 127 | 0.370 |
Why?
| | Wounds, Penetrating | 1 | 2012 | 73 | 0.370 |
Why?
| | Male | 38 | 2022 | 55555 | 0.370 |
Why?
| | Treatment Outcome | 16 | 2023 | 9084 | 0.370 |
Why?
| | Rats, Sprague-Dawley | 9 | 2015 | 2218 | 0.360 |
Why?
| | Patient Care Management | 1 | 2011 | 53 | 0.360 |
Why?
| | Carcinoma, Pancreatic Ductal | 1 | 2013 | 211 | 0.350 |
Why?
| | Wounds, Nonpenetrating | 2 | 2015 | 256 | 0.350 |
Why?
| | Patient Transfer | 1 | 2012 | 143 | 0.340 |
Why?
| | Female | 35 | 2021 | 59466 | 0.340 |
Why?
| | Mesentery | 4 | 2015 | 53 | 0.330 |
Why?
| | Risk Assessment | 9 | 2021 | 2967 | 0.320 |
Why?
| | Ischemia | 5 | 2022 | 362 | 0.320 |
Why?
| | Platelet Aggregation Inhibitors | 5 | 2022 | 401 | 0.310 |
Why?
| | Thrombophilia | 2 | 2021 | 67 | 0.290 |
Why?
| | Software | 1 | 2011 | 529 | 0.280 |
Why?
| | Anticoagulants | 4 | 2021 | 550 | 0.280 |
Why?
| | Computer Simulation | 1 | 2011 | 872 | 0.280 |
Why?
| | Rats | 8 | 2014 | 4958 | 0.280 |
Why?
| | Risk Factors | 9 | 2021 | 8628 | 0.280 |
Why?
| | Blood Platelets | 4 | 2014 | 351 | 0.270 |
Why?
| | Prospective Studies | 9 | 2022 | 6217 | 0.270 |
Why?
| | Adaptation, Psychological | 2 | 2021 | 547 | 0.270 |
Why?
| | Education, Medical, Graduate | 2 | 2021 | 368 | 0.260 |
Why?
| | Adenocarcinoma | 1 | 2012 | 795 | 0.260 |
Why?
| | Pancreatic Neoplasms | 1 | 2013 | 731 | 0.260 |
Why?
| | Aged | 10 | 2021 | 19061 | 0.250 |
Why?
| | Middle Aged | 20 | 2021 | 26719 | 0.250 |
Why?
| | Fibrinolysis | 3 | 2020 | 158 | 0.250 |
Why?
| | Diagnosis, Differential | 3 | 2015 | 1342 | 0.250 |
Why?
| | Lower Extremity | 3 | 2023 | 335 | 0.250 |
Why?
| | Retrospective Studies | 8 | 2023 | 12542 | 0.240 |
Why?
| | Kidney | 1 | 2012 | 1188 | 0.240 |
Why?
| | Time Factors | 7 | 2022 | 6112 | 0.240 |
Why?
| | Angiography | 2 | 2023 | 174 | 0.240 |
Why?
| | Adult | 23 | 2021 | 30528 | 0.240 |
Why?
| | Venous Thromboembolism | 2 | 2021 | 231 | 0.240 |
Why?
| | Health Surveys | 3 | 2021 | 443 | 0.240 |
Why?
| | Occupational Health | 3 | 2021 | 165 | 0.230 |
Why?
| | Brain Injuries | 3 | 2014 | 461 | 0.220 |
Why?
| | Injury Severity Score | 7 | 2016 | 499 | 0.220 |
Why?
| | Heparin, Low-Molecular-Weight | 2 | 2014 | 28 | 0.220 |
Why?
| | Physician-Patient Relations | 2 | 2021 | 462 | 0.220 |
Why?
| | Endarterectomy, Carotid | 1 | 2023 | 42 | 0.210 |
Why?
| | Hospital Mortality | 2 | 2021 | 776 | 0.210 |
Why?
| | Prevalence | 3 | 2020 | 2249 | 0.210 |
Why?
| | Arachidonic Acid | 2 | 2014 | 116 | 0.210 |
Why?
| | Ischemic Attack, Transient | 1 | 2023 | 62 | 0.200 |
Why?
| | Carotid Stenosis | 1 | 2023 | 79 | 0.200 |
Why?
| | Specialties, Surgical | 2 | 2020 | 70 | 0.200 |
Why?
| | Blood Coagulation Tests | 2 | 2020 | 57 | 0.200 |
Why?
| | Observational Studies as Topic | 1 | 2022 | 90 | 0.200 |
Why?
| | Iliac Aneurysm | 1 | 2022 | 17 | 0.200 |
Why?
| | United States | 9 | 2020 | 12176 | 0.200 |
Why?
| | Arterial Occlusive Diseases | 1 | 2022 | 74 | 0.200 |
Why?
| | Point-of-Care Systems | 3 | 2012 | 136 | 0.200 |
Why?
| | Peripheral Vascular Diseases | 1 | 2022 | 97 | 0.190 |
Why?
| | Arteriovenous Fistula | 1 | 2021 | 29 | 0.190 |
Why?
| | Aortic Rupture | 1 | 2021 | 25 | 0.190 |
Why?
| | Iliac Vein | 1 | 2021 | 8 | 0.190 |
Why?
| | Work Capacity Evaluation | 1 | 2020 | 11 | 0.180 |
Why?
| | Culturally Competent Care | 1 | 2021 | 48 | 0.180 |
Why?
| | Physicians, Women | 1 | 2021 | 55 | 0.180 |
Why?
| | Catheters | 1 | 2021 | 63 | 0.180 |
Why?
| | Vena Cava, Inferior | 1 | 2021 | 56 | 0.180 |
Why?
| | Tenotomy | 1 | 2020 | 13 | 0.180 |
Why?
| | Iatrogenic Disease | 1 | 2020 | 49 | 0.170 |
Why?
| | Workload | 3 | 2021 | 132 | 0.170 |
Why?
| | Tendon Transfer | 1 | 2020 | 43 | 0.170 |
Why?
| | Societies, Medical | 2 | 2020 | 663 | 0.170 |
Why?
| | Catheterization, Peripheral | 1 | 2021 | 101 | 0.170 |
Why?
| | Posture | 1 | 2020 | 152 | 0.170 |
Why?
| | International Cooperation | 1 | 2020 | 171 | 0.160 |
Why?
| | Decompression, Surgical | 1 | 2020 | 93 | 0.160 |
Why?
| | Thromboembolism | 1 | 2020 | 92 | 0.160 |
Why?
| | Mentors | 1 | 2021 | 156 | 0.160 |
Why?
| | Catheterization, Central Venous | 1 | 2020 | 83 | 0.160 |
Why?
| | Venous Thrombosis | 1 | 2021 | 140 | 0.160 |
Why?
| | Surveys and Questionnaires | 7 | 2022 | 4620 | 0.160 |
Why?
| | Partnership Practice | 1 | 2018 | 3 | 0.160 |
Why?
| | Infection Control | 1 | 2020 | 135 | 0.160 |
Why?
| | Insurance Benefits | 1 | 2018 | 11 | 0.160 |
Why?
| | Time-to-Treatment | 1 | 2020 | 147 | 0.160 |
Why?
| | Physical Endurance | 1 | 2020 | 232 | 0.160 |
Why?
| | Acute Disease | 4 | 2021 | 910 | 0.160 |
Why?
| | Walking | 1 | 2022 | 422 | 0.160 |
Why?
| | Health Services Needs and Demand | 1 | 2020 | 243 | 0.150 |
Why?
| | Pain Measurement | 1 | 2020 | 444 | 0.150 |
Why?
| | Medically Uninsured | 1 | 2018 | 121 | 0.150 |
Why?
| | Triage | 1 | 2020 | 199 | 0.150 |
Why?
| | Delivery of Health Care, Integrated | 1 | 2020 | 228 | 0.150 |
Why?
| | Biomechanical Phenomena | 1 | 2020 | 668 | 0.140 |
Why?
| | Insurance Coverage | 1 | 2018 | 200 | 0.140 |
Why?
| | Statistics, Nonparametric | 3 | 2014 | 385 | 0.140 |
Why?
| | Nutrition Assessment | 1 | 2017 | 75 | 0.140 |
Why?
| | Insurance, Health | 1 | 2018 | 244 | 0.140 |
Why?
| | Purinergic P2Y Receptor Antagonists | 2 | 2014 | 62 | 0.140 |
Why?
| | Recovery of Function | 1 | 2020 | 574 | 0.130 |
Why?
| | Resuscitation | 2 | 2016 | 252 | 0.130 |
Why?
| | Sex Factors | 1 | 2021 | 1715 | 0.130 |
Why?
| | Cohort Studies | 3 | 2022 | 4894 | 0.130 |
Why?
| | Practice Guidelines as Topic | 2 | 2021 | 1394 | 0.130 |
Why?
| | Myocardial Infarction | 1 | 2022 | 927 | 0.130 |
Why?
| | Hemostatic Techniques | 1 | 2016 | 40 | 0.130 |
Why?
| | Motor Activity | 1 | 2020 | 640 | 0.130 |
Why?
| | Exsanguination | 2 | 2012 | 16 | 0.130 |
Why?
| | Receptor, PAR-2 | 1 | 2015 | 8 | 0.130 |
Why?
| | Phosphopyruvate Hydratase | 1 | 2015 | 30 | 0.130 |
Why?
| | Geriatric Assessment | 1 | 2017 | 176 | 0.130 |
Why?
| | Animals | 10 | 2015 | 31695 | 0.120 |
Why?
| | Biomedical Research | 1 | 2021 | 585 | 0.120 |
Why?
| | Plasminogen | 1 | 2015 | 33 | 0.120 |
Why?
| | Systemic Inflammatory Response Syndrome | 1 | 2015 | 70 | 0.120 |
Why?
| | Microcirculation | 1 | 2015 | 135 | 0.120 |
Why?
| | Stroke | 1 | 2023 | 1021 | 0.120 |
Why?
| | Kaplan-Meier Estimate | 1 | 2017 | 811 | 0.120 |
Why?
| | Medicaid | 1 | 2018 | 406 | 0.120 |
Why?
| | Down-Regulation | 1 | 2017 | 594 | 0.120 |
Why?
| | Blood Vessel Prosthesis | 3 | 2022 | 112 | 0.120 |
Why?
| | Frailty | 1 | 2017 | 115 | 0.120 |
Why?
| | Thrombin | 2 | 2015 | 139 | 0.120 |
Why?
| | Odds Ratio | 1 | 2017 | 953 | 0.120 |
Why?
| | Proportional Hazards Models | 1 | 2017 | 1075 | 0.110 |
Why?
| | Postoperative Complications | 2 | 2021 | 2128 | 0.110 |
Why?
| | Chi-Square Distribution | 2 | 2012 | 493 | 0.110 |
Why?
| | Prosthesis Design | 3 | 2022 | 285 | 0.110 |
Why?
| | Medicare | 1 | 2018 | 665 | 0.110 |
Why?
| | Registries | 1 | 2021 | 1767 | 0.110 |
Why?
| | Aged, 80 and over | 4 | 2020 | 6344 | 0.110 |
Why?
| | Muscle, Skeletal | 1 | 2022 | 1472 | 0.110 |
Why?
| | Bronchoalveolar Lavage Fluid | 2 | 2012 | 590 | 0.110 |
Why?
| | Subclavian Artery | 1 | 2013 | 29 | 0.110 |
Why?
| | Carotid Artery, Common | 1 | 2013 | 29 | 0.110 |
Why?
| | Comorbidity | 2 | 2021 | 1448 | 0.110 |
Why?
| | Fibrinogen | 1 | 2014 | 154 | 0.110 |
Why?
| | Colorado | 5 | 2016 | 4099 | 0.110 |
Why?
| | History, 17th Century | 1 | 2012 | 15 | 0.100 |
Why?
| | Stress, Psychological | 1 | 2020 | 944 | 0.100 |
Why?
| | History, 18th Century | 1 | 2012 | 18 | 0.100 |
Why?
| | Isoflurane | 1 | 2012 | 8 | 0.100 |
Why?
| | Proteomics | 3 | 2015 | 836 | 0.100 |
Why?
| | Anesthetics, Inhalation | 1 | 2012 | 14 | 0.100 |
Why?
| | History, 19th Century | 1 | 2012 | 54 | 0.100 |
Why?
| | Depression | 1 | 2020 | 1133 | 0.100 |
Why?
| | Sigmoid Diseases | 1 | 2012 | 10 | 0.100 |
Why?
| | Social Responsibility | 1 | 2012 | 45 | 0.100 |
Why?
| | Neutrophil Infiltration | 1 | 2012 | 96 | 0.100 |
Why?
| | Narration | 1 | 2012 | 44 | 0.100 |
Why?
| | Arachidonate 5-Lipoxygenase | 1 | 2012 | 45 | 0.100 |
Why?
| | Nebulizers and Vaporizers | 1 | 2012 | 78 | 0.100 |
Why?
| | Practice Patterns, Physicians' | 1 | 2020 | 1177 | 0.100 |
Why?
| | Biopsy, Needle | 1 | 2012 | 182 | 0.100 |
Why?
| | 12-Hydroxy-5,8,10,14-eicosatetraenoic Acid | 1 | 2011 | 3 | 0.100 |
Why?
| | Survival Rate | 2 | 2016 | 1644 | 0.100 |
Why?
| | Trauma Severity Indices | 1 | 2012 | 114 | 0.100 |
Why?
| | Blood Transfusion, Autologous | 1 | 2011 | 19 | 0.100 |
Why?
| | Chronic Disease | 2 | 2021 | 1578 | 0.100 |
Why?
| | Multivariate Analysis | 2 | 2013 | 1430 | 0.100 |
Why?
| | Hydroxyeicosatetraenoic Acids | 1 | 2011 | 40 | 0.100 |
Why?
| | Efficiency, Organizational | 1 | 2012 | 125 | 0.100 |
Why?
| | Social Values | 1 | 2012 | 36 | 0.100 |
Why?
| | Renal Replacement Therapy | 1 | 2012 | 66 | 0.100 |
Why?
| | Random Allocation | 1 | 2012 | 335 | 0.100 |
Why?
| | Colectomy | 1 | 2012 | 86 | 0.100 |
Why?
| | Oxidative Stress | 3 | 2014 | 1076 | 0.100 |
Why?
| | Kidney Function Tests | 1 | 2012 | 140 | 0.100 |
Why?
| | Extravascular Lung Water | 1 | 2011 | 8 | 0.090 |
Why?
| | History, 20th Century | 1 | 2012 | 264 | 0.090 |
Why?
| | Biomarkers | 3 | 2017 | 3408 | 0.090 |
Why?
| | Docosahexaenoic Acids | 1 | 2011 | 69 | 0.090 |
Why?
| | Proteome | 1 | 2014 | 339 | 0.090 |
Why?
| | Disseminated Intravascular Coagulation | 1 | 2011 | 30 | 0.090 |
Why?
| | Pancreatectomy | 1 | 2013 | 171 | 0.090 |
Why?
| | Abdominal Pain | 1 | 2012 | 135 | 0.090 |
Why?
| | Abdominal Injuries | 1 | 2012 | 108 | 0.090 |
Why?
| | Hypothermia | 1 | 2011 | 38 | 0.090 |
Why?
| | Administration, Inhalation | 1 | 2012 | 641 | 0.090 |
Why?
| | Efficiency | 1 | 2011 | 84 | 0.090 |
Why?
| | Aorta, Thoracic | 1 | 2013 | 256 | 0.090 |
Why?
| | Interprofessional Relations | 1 | 2012 | 249 | 0.090 |
Why?
| | Trauma Centers | 4 | 2016 | 362 | 0.090 |
Why?
| | Quality Assurance, Health Care | 1 | 2012 | 311 | 0.090 |
Why?
| | Superoxides | 1 | 2011 | 214 | 0.090 |
Why?
| | Cross-Sectional Studies | 4 | 2020 | 4405 | 0.090 |
Why?
| | Endothelial Cells | 1 | 2015 | 681 | 0.090 |
Why?
| | Acidosis | 1 | 2011 | 88 | 0.090 |
Why?
| | Quality Improvement | 2 | 2021 | 950 | 0.090 |
Why?
| | Logistic Models | 2 | 2012 | 1840 | 0.080 |
Why?
| | Thrombosis | 1 | 2013 | 298 | 0.080 |
Why?
| | Models, Animal | 1 | 2011 | 344 | 0.080 |
Why?
| | Recurrence | 1 | 2012 | 935 | 0.080 |
Why?
| | Safety | 1 | 2011 | 297 | 0.080 |
Why?
| | Disease Models, Animal | 3 | 2014 | 3531 | 0.080 |
Why?
| | Adolescent | 5 | 2020 | 17831 | 0.080 |
Why?
| | Reperfusion Injury | 1 | 2011 | 255 | 0.080 |
Why?
| | Tissue and Organ Procurement | 1 | 2012 | 228 | 0.080 |
Why?
| | Lymph Nodes | 1 | 2011 | 419 | 0.080 |
Why?
| | Immunohistochemistry | 1 | 2012 | 1629 | 0.080 |
Why?
| | Sensitivity and Specificity | 1 | 2012 | 1691 | 0.070 |
Why?
| | Lung | 3 | 2015 | 3558 | 0.070 |
Why?
| | Prognosis | 2 | 2013 | 3328 | 0.070 |
Why?
| | Evidence-Based Medicine | 1 | 2011 | 668 | 0.070 |
Why?
| | Chromatography, Liquid | 3 | 2014 | 347 | 0.070 |
Why?
| | Patient Care Team | 1 | 2011 | 517 | 0.070 |
Why?
| | Communication | 1 | 2012 | 744 | 0.070 |
Why?
| | Tandem Mass Spectrometry | 3 | 2014 | 411 | 0.070 |
Why?
| | Incidence | 1 | 2012 | 2311 | 0.060 |
Why?
| | Clinical Competence | 1 | 2012 | 893 | 0.060 |
Why?
| | Electronic Health Records | 1 | 2012 | 800 | 0.060 |
Why?
| | Databases, Factual | 2 | 2021 | 1124 | 0.060 |
Why?
| | Reproducibility of Results | 1 | 2011 | 2762 | 0.060 |
Why?
| | Platelet Function Tests | 2 | 2014 | 24 | 0.060 |
Why?
| | Aortography | 2 | 2013 | 50 | 0.050 |
Why?
| | Receptors, Purinergic P2 | 2 | 2013 | 20 | 0.050 |
Why?
| | Platelet Activation | 2 | 2014 | 68 | 0.050 |
Why?
| | Mesenteric Artery, Inferior | 1 | 2022 | 2 | 0.050 |
Why?
| | Limb Salvage | 1 | 2022 | 52 | 0.050 |
Why?
| | Tomography, X-Ray Computed | 3 | 2018 | 2279 | 0.050 |
Why?
| | Iliac Artery | 1 | 2022 | 43 | 0.050 |
Why?
| | Carotid Arteries | 1 | 2023 | 180 | 0.050 |
Why?
| | Off-Label Use | 1 | 2022 | 51 | 0.050 |
Why?
| | Mitochondrial Proteins | 2 | 2015 | 219 | 0.050 |
Why?
| | Product Labeling | 1 | 2021 | 5 | 0.050 |
Why?
| | Blood Component Transfusion | 2 | 2012 | 78 | 0.050 |
Why?
| | Phlebography | 1 | 2021 | 34 | 0.050 |
Why?
| | Rivaroxaban | 1 | 2022 | 211 | 0.050 |
Why?
| | Depersonalization | 1 | 2020 | 7 | 0.050 |
Why?
| | Work-Life Balance | 1 | 2020 | 10 | 0.050 |
Why?
| | Young Adult | 5 | 2014 | 10455 | 0.050 |
Why?
| | Protective Factors | 1 | 2021 | 87 | 0.050 |
Why?
| | Brazil | 1 | 2020 | 89 | 0.040 |
Why?
| | Fibrin Clot Lysis Time | 1 | 2020 | 8 | 0.040 |
Why?
| | Partial Thromboplastin Time | 1 | 2020 | 51 | 0.040 |
Why?
| | Personal Protective Equipment | 1 | 2020 | 49 | 0.040 |
Why?
| | Aspirin | 1 | 2022 | 324 | 0.040 |
Why?
| | Heparin | 1 | 2021 | 224 | 0.040 |
Why?
| | Fibrin Fibrinogen Degradation Products | 1 | 2020 | 80 | 0.040 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2014 | 1842 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2021 | 268 | 0.040 |
Why?
| | Psychiatric Status Rating Scales | 1 | 2020 | 482 | 0.040 |
Why?
| | Hemorrhage | 1 | 2022 | 620 | 0.040 |
Why?
| | Health Care Surveys | 1 | 2020 | 539 | 0.040 |
Why?
| | Popliteal Artery | 1 | 2018 | 57 | 0.040 |
Why?
| | Stents | 1 | 2022 | 475 | 0.040 |
Why?
| | Global Health | 1 | 2020 | 287 | 0.040 |
Why?
| | Patient Protection and Affordable Care Act | 1 | 2018 | 99 | 0.040 |
Why?
| | Pilot Projects | 1 | 2022 | 1372 | 0.040 |
Why?
| | Host-Pathogen Interactions | 1 | 2020 | 295 | 0.040 |
Why?
| | Career Choice | 1 | 2019 | 177 | 0.040 |
Why?
| | Guideline Adherence | 1 | 2021 | 490 | 0.030 |
Why?
| | Clinical Trials as Topic | 1 | 2021 | 931 | 0.030 |
Why?
| | Renal Dialysis | 1 | 2020 | 374 | 0.030 |
Why?
| | Emotions | 1 | 2020 | 472 | 0.030 |
Why?
| | Case-Control Studies | 2 | 2014 | 3003 | 0.030 |
Why?
| | Intensive Care Units | 1 | 2020 | 617 | 0.030 |
Why?
| | Alarmins | 1 | 2015 | 25 | 0.030 |
Why?
| | Bacterial Translocation | 1 | 2015 | 36 | 0.030 |
Why?
| | Pain | 1 | 2020 | 705 | 0.030 |
Why?
| | Tranexamic Acid | 1 | 2015 | 39 | 0.030 |
Why?
| | Intercellular Adhesion Molecule-1 | 1 | 2015 | 154 | 0.030 |
Why?
| | Inflammation | 2 | 2015 | 2478 | 0.030 |
Why?
| | Mesenteric Artery, Superior | 1 | 2013 | 12 | 0.030 |
Why?
| | Renal Artery | 1 | 2013 | 26 | 0.030 |
Why?
| | Extracellular Matrix Proteins | 1 | 2014 | 127 | 0.030 |
Why?
| | Age Factors | 1 | 2020 | 2894 | 0.030 |
Why?
| | Glasgow Coma Scale | 1 | 2014 | 151 | 0.030 |
Why?
| | Cluster Analysis | 1 | 2014 | 455 | 0.030 |
Why?
| | Platelet Count | 1 | 2013 | 81 | 0.030 |
Why?
| | Balloon Occlusion | 1 | 2013 | 26 | 0.030 |
Why?
| | Anastomosis, Surgical | 1 | 2013 | 136 | 0.030 |
Why?
| | Blood Proteins | 1 | 2014 | 231 | 0.030 |
Why?
| | Receptors, Purinergic P2Y12 | 1 | 2012 | 6 | 0.030 |
Why?
| | Reference Values | 1 | 2014 | 742 | 0.030 |
Why?
| | Health Services Accessibility | 1 | 2018 | 761 | 0.030 |
Why?
| | Leukotriene C4 | 1 | 2012 | 12 | 0.030 |
Why?
| | Leukotriene B4 | 1 | 2012 | 48 | 0.030 |
Why?
| | Lipoxygenase Inhibitors | 1 | 2012 | 36 | 0.030 |
Why?
| | Ticlopidine | 1 | 2012 | 55 | 0.020 |
Why?
| | Eicosanoids | 1 | 2012 | 54 | 0.020 |
Why?
| | Peroxidase | 1 | 2012 | 163 | 0.020 |
Why?
| | Flow Cytometry | 1 | 2015 | 1083 | 0.020 |
Why?
| | Cell Membrane | 1 | 2015 | 680 | 0.020 |
Why?
| | Dinoprostone | 1 | 2012 | 184 | 0.020 |
Why?
| | Fluorescent Antibody Technique | 1 | 2012 | 397 | 0.020 |
Why?
| | Oxidation-Reduction | 1 | 2014 | 923 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2014 | 633 | 0.020 |
Why?
| | Quality of Life | 1 | 2022 | 2353 | 0.020 |
Why?
| | Cerebrovascular Circulation | 1 | 2013 | 221 | 0.020 |
Why?
| | Acute-Phase Proteins | 1 | 2011 | 64 | 0.020 |
Why?
| | Electrophoresis, Polyacrylamide Gel | 1 | 2011 | 318 | 0.020 |
Why?
| | Hemolysis | 1 | 2011 | 146 | 0.020 |
Why?
| | Waiting Lists | 1 | 2012 | 211 | 0.020 |
Why?
| | Indoles | 1 | 2012 | 304 | 0.020 |
Why?
| | Membrane Glycoproteins | 1 | 2011 | 430 | 0.020 |
Why?
| | Mice, Transgenic | 1 | 2012 | 1947 | 0.020 |
Why?
| | Carrier Proteins | 1 | 2011 | 695 | 0.020 |
Why?
| | Follow-Up Studies | 1 | 2013 | 4411 | 0.010 |
Why?
| | Cells, Cultured | 1 | 2011 | 3881 | 0.010 |
Why?
| | Mice, Inbred C57BL | 1 | 2012 | 4689 | 0.010 |
Why?
| | Mice | 1 | 2012 | 14860 | 0.010 |
Why?
|
|
Wohlauer's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|